Case Report
Journal of Pharmacy Practice and Community Medicine
Vol. 12
Issue 3
2026
pp. 176-179
Open Access

A Case Report on Decompensated Chronic Liver Disease with Budd–Chiari Syndrome

Mallela Maharshi1,Joel Nathan Thaneti1,Padigala Ramya Jyothi1,A. G. N. Harshita Devi1,Nani Deepa1,Ganjala Hemalatha1,Jonnadula Kedareswari1,Nemalikanti Elizabeth Mary Paul1,Manchikanti Hima Sathwika1,Vijaya Bhaskar Jirra1
1Department of Pharmacology and Pharmacy Practice, Nirmala College of Pharmacy, Atmakuru, Mangalagiri, Guntur, Andhra Pradesh, INDIA.
Correspondence:

*Padigala Ramya Jyothi

Department of Pharmacology and Pharmacy Practice, Nirmala College of Pharmacy, Atmakuru, Mangalagiri, Guntur, Andhra Pradesh, INDIA.

padigalaramya5@gmail.com

Copyright:

2026 Author(s)

Check for updates
Published:22/05/2026
Received: Not set
Accepted: Not set

Abstract

The rare illness, known as Budd-Chiari Syndrome (BCS), is characterized by hepatic venous outflow tract obstruction and can arise from the right atrium, inferior vena cava, or the tiny hepatic veins within the liver. It is an uncommon liver condition in which obstructions, typically caused by blood clots, restrict the hepatic veins, preventing blood from exiting the liver and returning to the heart. As a result, the liver enlarges (hepatomegaly), accumulates fluid (ascites), and causes abdominal pain. We present a rare case of a young female diagnosed with decompensated chronic liver disease secondary to Budd–Chiari syndrome, who came with the features of abdominal distension and weight loss, along with a Model for end stage liver disease Na score of 20 and splenomegaly with portal hypertension. The diagnosis was confirmed by Doppler ultrasonography and contrast-enhanced CT of the abdomen, supported by abnormal laboratory parameters including prolonged prothrombin time with elevated INR, decreased serum albumin and total protein levels, and elevated WBC count, lymphocytes, GGT, and bilirubin. Management included anticoagulants, antibiotics, statins, proton pump inhibitors, β blockers, hepatoprotective agents, diuretics, and other supportive care, with a step-up approach planned for hepatic venous outflow restoration to prevent disease progression.

Share on Mobile

Scan to access on mobile

Keywords

Budd-Chairi syndrome
Ascities
Hepatomegaly
Liver
Endoluminal venous lesion

Content

No content available

Related Articles